PT-141 (Bremelanotide) · Research brief

PT-141 (Bremelanotide): Mechanism, Research & Lab Handling

Real Peptides Research TeamEditorial

Updated September 5, 202610 min read

50 WORDS

Short answer

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide and non-selective melanocortin receptor agonist, structurally derived from the alpha-melanocyte-stimulating hormone analog Melanotan II. Research examines its central nervous system activity at melanocortin receptors, particularly signaling implicated in sexual arousal pathways, alongside melanocortin biology more broadly. It is supplied for laboratory research only.

Key takeaways

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide analog of alpha-MSH, structurally derived from the melanocortin agonist Melanotan II.
Its reported mechanism is central rather than vascular: non-selective melanocortin receptor agonism, with MC3R and MC4R signaling in hypothalamic circuits implicated in arousal.
Published work spans female sexual desire trials, early erectile function studies, and broader melanocortin biology; several 2021-2024 reappraisals argue reported effect sizes were small and of debatable clinical meaning.
Bremelanotide exists as an approved prescription product in one narrow indication, but research-grade PT-141 sold by peptide suppliers is not that product and is supplied for laboratory research use only.
Handling centers on lyophilized cold storage, gentle reconstitution, aliquoting to limit freeze-thaw, and light protection.
Supplier evaluation should rest on batch-specific third-party COAs with HPLC purity, mass spectrometry identity confirmation, and traceable lot numbering.

What PT-141 Is and Where It Came From

PT-141 belongs to the melanocortin peptide family, a group of small signaling molecules that includes alpha-MSH and ACTH and that acts across five known receptor subtypes, MC1R through MC5R. These receptors govern an unusually wide range of biology: pigmentation, steroidogenesis, energy balance, inflammation, exocrine function, and — the reason PT-141 exists as a distinct research compound — components of central sexual arousal.

The compound emerged from work on Melanotan II, a superpotent cyclic alpha-MSH analog originally investigated for pigmentation research. Investigators observed that the molecule produced effects unrelated to tanning, and attention shifted to the metabolite that retained those effects while losing much of the pigmentation-driving MC1R potency. That metabolite, in which the C-terminal amide of Melanotan II is replaced by a free acid, became PT-141 and later carried the international nonproprietary name bremelanotide.

Structurally it is described as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a molecular formula of C50H68N14O10 and a molecular weight near 1025 g/mol. Two features matter for laboratory work. The lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring, which improves stability relative to a linear sequence and helps preserve the receptor-binding conformation. The D-phenylalanine substitution similarly resists enzymatic cleavage. Even so, PT-141 is a peptide: it is supplied lyophilized, it is sensitive to heat, moisture, and repeated freeze-thaw, and it does not behave like a small-molecule drug substance on the bench.

Reported Mechanism of Action

The defining characteristic of PT-141 in the literature is that its proposed site of action is central rather than peripheral. Phosphodiesterase type 5 inhibitors act downstream on vascular smooth muscle through the nitric oxide-cGMP pathway; they modulate the hemodynamics of an already-initiated response. PT-141 is described instead as an agonist at melanocortin receptors expressed in the brain, with MC4R — and to a lesser and less well-characterized degree MC3R — considered the receptors of principal interest.

Preclinical and mechanistic reviews, including work summarized in the 2022 CNS Spectrums literature on the neurobiology of bremelanotide, describe activity within hypothalamic circuitry: the medial preoptic area and paraventricular nucleus are the regions most often named. The proposed downstream consequence is modulation of dopaminergic signaling in pathways associated with appetitive and motivational behavior, rather than direct vasodilation. This framing is why the compound is discussed in terms of desire and arousal circuitry rather than erectile hemodynamics, and why comparisons to PDE5 inhibitors are best treated as comparisons of two entirely different pharmacological categories.

Attribute	PT-141 (Bremelanotide)	PDE5 inhibitors
Molecular class	Cyclic heptapeptide	Small-molecule enzyme inhibitor
Proposed primary site	Central melanocortin receptors	Peripheral vascular smooth muscle
Pathway implicated	MC3R/MC4R signaling, hypothalamic circuits	Nitric oxide-cGMP degradation
Typical research framing	Desire and arousal circuitry	Erectile hemodynamics

Two caveats deserve emphasis. First, PT-141 is not receptor-selective; agonism across multiple melanocortin subtypes complicates attribution of any observed effect to a single receptor. Second, mechanistic models built largely on rodent data and receptor pharmacology remain inferential when extended to human physiology.

What the Research Literature Examines

Female sexual desire

The largest and most scrutinized body of work concerns hypoactive sexual desire disorder in premenopausal women. A phase III clinical development program supported a regulatory submission, and the 2020 Annals of Pharmacotherapy review documents the approval of bremelanotide for that narrow indication. Subsequent evaluations, including a 2022 Neurology International review and a 2023 Expert Opinion on Pharmacotherapy evaluation, summarize the trial design, outcome instruments, and tolerability data.

That literature is genuinely contested. A 2021 re-analysis in the Journal of Sex Research and a 2024 paper in the same journal argue that the observed differences on desire and distress scales were small in magnitude and of questionable clinical significance, and a 2021 Drug and Therapeutics Bulletin commentary criticizes the regulatory precedent set by approvals in this therapeutic space. Researchers reading this hub should treat the effect-size debate as unresolved rather than settled, and should read the primary trial reports alongside the critiques.

Erectile function and male arousal

Earlier clinical work explored intranasal delivery in men, and this line of investigation is frequently cited as the origin of the compound's popular reputation. Published accounts report that the intranasal program was not carried forward, with blood pressure observations among the stated reasons. Evidence in this area is older, smaller, and considerably less developed than the female desire program; it should be characterized as preliminary.

Melanocortin biology beyond sexual function

Because MC4R sits at the center of energy homeostasis, and because melanocortin signaling touches inflammation and cardiovascular regulation, PT-141 appears in exploratory work as a tool compound for probing melanocortin pharmacology generally. Findings in these areas are largely confined to animal models and receptor-level studies, and translation to human physiology has not been established.

Safety and tolerability signals

A 2022 Journal of Women's Health analysis pooled safety data across the clinical development program. The tolerability signals most consistently discussed in the literature are nausea, flushing, headache, and injection-site reactions, along with transient elevations in blood pressure and compensatory heart rate changes. Reports of hyperpigmentation, consistent with residual MC1R activity, also appear. These are observations from a specific clinical program under supervised conditions and should not be extrapolated to unstudied contexts.

Laboratory Handling: Reconstitution and Storage

PT-141 ships as a white lyophilized powder in a sealed vial, often as a thin cake or film that can be nearly invisible against the glass. Absence of a visible cake is not, by itself, evidence of a problem; mass is confirmed by the certificate of analysis, not by eye.

General handling principles that apply across peptide laboratories:

Storage before reconstitution. Lyophilized material is stored cold and dry, protected from light, with long-term storage typically at freezer temperatures. Vials are allowed to equilibrate to ambient temperature before opening to limit condensation onto the powder.
Diluent selection. Bacteriostatic water is standard where a solution will be accessed repeatedly over time; sterile water is used where a single-use preparation is intended. The choice affects how long a solution is considered usable.
Technique. Diluent is directed down the vial wall rather than jetted onto the peptide cake, and the vial is swirled or rolled gently until dissolution is complete. Shaking introduces shear and foaming, both of which are avoided.
After reconstitution. Solutions are refrigerated, kept out of light, and aliquoted where appropriate so that a working stock is not subjected to repeated freeze-thaw cycles. Any cloudiness, precipitate, or visible particulate is treated as a reason to discontinue use of that preparation.

Concentration selection, reconstitution arithmetic, expected solution appearance, and time-to-degradation questions are covered in dedicated articles across this library. This hub deliberately states no amounts.

Regulatory and Research-Use Status

Two facts need to be held simultaneously and without blurring. Bremelanotide exists as an approved prescription pharmaceutical product in one narrow indication, manufactured under pharmaceutical GMP, prescribed and monitored by clinicians. Separately, research-grade PT-141 is sold by peptide suppliers as a laboratory chemical. These are not the same material, the same manufacturing standard, or the same regulatory category.

Research-grade PT-141 supplied by Real Peptides is intended for research use only. It is not a drug product, not a dietary supplement, and not approved by any regulatory authority for the uses discussed on this page or anywhere in this library. It is not intended for human or veterinary consumption, diagnostic procedures, or therapeutic application. Nothing here constitutes medical advice or an efficacy claim; the mechanistic and clinical material above is a summary of published literature, including literature that disputes its own conclusions.

How Researchers Evaluate Supplier Quality

Peptide quality is not visible in a vial, and it is not established by a price point or a brand claim. It is established by documentation tied to the specific lot in hand.

Check	What it establishes	What to look for
HPLC purity	Proportion of the target peptide relative to synthesis-related impurities	A chromatogram with labeled main peak and integrated area, not a bare percentage
Mass spectrometry	Identity — that the peptide present is the intended sequence	Observed mass consistent with the expected molecular weight
Batch traceability	That the COA corresponds to the vial received	A lot number on the label matching the lot number on the certificate
Third-party testing	Independence from the seller's own claims	An external laboratory named on the report
Supporting assays	Residual process contaminants and moisture load	Water content, residual solvent, and counter-ion (acetate) data where provided

A useful heuristic: a supplier that publishes per-batch COAs from an independent laboratory is inviting verification, while a supplier offering a single undated certificate reused across all lots is not. Researchers who intend to publish or to build reproducible protocols should archive the COA alongside the lot number and receipt date, because a purity figure is only meaningful when it can be attached to a specific batch.

Where the Open Questions Are

Honest summary of this compound requires naming what remains unknown:

Effect size and clinical meaning. The 2021 and 2024 re-analyses raise a substantive challenge to how trial outcomes were interpreted. This is an active methodological dispute, not a resolved question.
Receptor attribution. Because agonism is non-selective, the relative contributions of MC3R and MC4R — and the role of any off-target melanocortin activity — remain incompletely characterized.
Cardiovascular signaling. The transient blood pressure changes reported in clinical data are described more often than they are mechanistically explained.
Delivery route pharmacology. Comparative data across subcutaneous, intranasal, and oral routes is uneven, with the non-injectable routes far less developed.
Sex differences and long-term exposure. Most of the modern clinical dataset comes from one population in one indication; generalization beyond it is not supported.
Combination pharmacology. Interactions with other signaling peptides and with agents acting on unrelated pathways are largely uncharacterized in the published record.

For researchers, that list is the value of PT-141 as a study object: it is a well-defined molecule with a coherent proposed mechanism, a real clinical dataset, and a genuine scientific argument still running through the middle of it.

Research-grade PT-141 (Bremelanotide): Real Peptides supplies PT-141 (Bremelanotide) for laboratory research with a published third-party Certificate of Analysis for every batch. Research use only.

Explore PT-141 (Bremelanotide) research on Real Peptides

The articles below go deeper on the questions researchers ask most about PT-141 (Bremelanotide).

Reconstitution, storage & handling

Safety & side effects

Research timelines & mechanisms

Stacks & comparisons

Research questions

Buying & quality

References

Peer-reviewed sources on PT-141 (Bremelanotide) indexed in PubMed, listed for research context. Real Peptides supplies PT-141 (Bremelanotide) for laboratory research use only.

Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of sex research, 2024. PMID 36809187. doi:10.1080/00224499.2023.2175192
An evaluation of bremelanotide injection for the treatment of hypoactive sexual desire disorder. Expert opinion on pharmacotherapy, 2023. PMID 36242769. doi:10.1080/14656566.2022.2132144
Bremelanotide for Treatment of Female Hypoactive Sexual Desire. Neurology international, 2022. PMID 35076581. doi:10.3390/neurolint14010006
The neurobiology of bremelanotide for the treatment of hypoactive sexual desire disorder in premenopausal women. CNS spectrums, 2022. PMID 33455598. doi:10.1017/S109285292100002X
Safety Profile of Bremelanotide Across the Clinical Development Program. Journal of women's health (2002), 2022. PMID 35147466. doi:10.1089/jwh.2021.0191
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of women's health (2002), 2022. PMID 35230162. doi:10.1089/jwh.2021.0225
Re-Analyzing Phase III Bremelanotide Trials for "Hypoactive Sexual Desire Disorder" in Women. Journal of sex research, 2021. PMID 33678061. doi:10.1080/00224499.2021.1885601
Bremelanotide and flibanserin for low sexual desire in women: the fallacy of regulatory precedent. Drug and therapeutics bulletin, 2021. PMID 34642243. doi:10.1136/dtb.2021.000020

Questions

Chemically the active peptide is the same molecule, bremelanotide, but the products are not interchangeable. Vyleesi is a finished pharmaceutical manufactured under GMP, formulated, and prescribed for a specific approved indication. Research-grade PT-141 is a lyophilized laboratory chemical sold for research use only, without pharmaceutical formulation, clinical oversight, or approval for any human application.

They occupy different pharmacological categories. PDE5 inhibitors act peripherally, blocking cGMP breakdown in vascular smooth muscle to affect blood flow. PT-141 is described as a melanocortin receptor agonist acting centrally, with MC3R and MC4R signaling in hypothalamic regions implicated in arousal circuitry. One modulates hemodynamics downstream; the other is proposed to act upstream on neural signaling.

PT-141 is structurally derived from Melanotan II, a cyclic alpha-MSH analog studied in pigmentation research. PT-141 corresponds to the metabolite in which the C-terminal amide is replaced by a free acid, a change reported to substantially reduce MC1R-driven pigmentation potency while retaining melanocortin activity relevant to the arousal-related effects that prompted its separate development.

Re-analyses published in the Journal of Sex Research in 2021 and 2024, along with a 2021 Drug and Therapeutics Bulletin commentary, argue that differences observed on desire and distress instruments were small in magnitude and of debatable clinical meaning, and question the regulatory precedent involved. The dispute concerns interpretation and outcome-measure significance rather than data fabrication.

At minimum: an HPLC chromatogram with the integrated main peak and a stated purity figure, mass spectrometry data confirming identity against the expected molecular weight of roughly 1025 g/mol, and a lot number matching the vial label. Supporting data such as water content, residual solvent, and acetate content adds confidence, as does testing by a named independent laboratory.

A 2022 Journal of Women's Health analysis pooling safety data across the clinical development program describes nausea, flushing, headache, and injection-site reactions among the most frequently reported observations, alongside transient blood pressure elevations and reports of hyperpigmentation consistent with residual MC1R activity. These derive from supervised clinical settings and do not extrapolate to unstudied contexts.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA